Bank of America Cuts CVS Health Price Target by 5% to $95
Bank of America lowered its CVS Health price target from $100 to $95 while maintaining a buy rating, triggering a premarket gap down. Analysts maintain a consensus Moderate Buy with an average price target of $94.86 across twenty ratings, reflecting mixed outlooks.
1. Medicare Advantage Rate Proposal Sparks Steep Sell-Off
Investors reacted sharply after the Centers for Medicare & Medicaid Services proposed a near-flat average payment increase of just 0.09% for Medicare Advantage plans in 2027, well below expectations of 4%–6%. CVS shares plunged roughly 15% on January 27, trading over 20 million shares that day, as market participants assessed the direct revenue impact on the company’s pharmacy benefit management and health insurance segments. The proposed rate change could reduce Medicare Advantage payments by more than $700 million compared with a 4% increase scenario, intensifying pressure on CVS’s Caremark business and its Aetna unit.
2. Analyst Downgrades and Price Target Cuts Weigh on Sentiment
Bank of America lowered its 12-month price target on CVS from $100 to $95 while maintaining a Buy rating, leading to a pre-market gap down to around $75 per share on the following trading day. Concurrently, Sanford C. Bernstein reissued a Market Perform rating with a $91 target, and Barclays trimmed its target from $93 to $89. Despite positive signals from TD Cowen and Evercore ISI, which upped their targets to $105 and $95 respectively, the consensus among 24 analysts on MarketBeat.com now sits at a Moderate Buy with an average target near $95, indicating limited near-term upside.
3. Underlying Fundamentals Provide Partial Support
CVS reported better-than-expected results in its most recent quarter, delivering $102.9 billion in revenue and $1.60 earnings per share versus consensus of $98.9 billion and $1.36. The company raised full-year EPS guidance to a range of $6.55–$6.65, underpinned by double-digit growth in pharmacy services and margin expansion at its HealthHUB clinics. Management reiterated its plan to achieve $3 billion in cost synergies by 2025 and target a leverage ratio below 3x net debt to EBITDA, partially counterbalancing regulatory headwinds.
4. Institutional Ownership Remains High Amid Volatility
Major asset managers continued to hold large positions despite the recent sell-off. Vanguard increased its stake by 1.7% to 120.4 million shares, while Capital World Investors and State Street added 1.4 million and 150,000 shares respectively in the past two quarters. Institutional investors now control over 80% of CVS’s outstanding shares, a sign that long-term holders remain committed to the company’s integrated health care model even as short-term volatility spikes.